Pharmacy World and Science

, Volume 24, Issue 3, pp 87–94 | Cite as

Effectiveness and safety of bemiparin versus low-molecular weight heparins in orthopaedic surgery

  • R. Ferriols-Lisart
  • F. Ferriols-Lisart
  • V. Jimnez-Torres


Objective: To evaluate the effectiveness and safety of bemiparin in the prophylaxis of thromboembolism in orthopaedic surgery with respect to other low-molecular-weight heparins.Methods: A meta-analysis of effectiveness and safety of low-molecular weight heparins versus standard heparin in orthopaedic surgery was performed. A literature search was done of Medline and Excerpta Medica from 1988 to 1998 . Only controlled clinical trials were selected for meta-analysis. Differences between groups were expressed as odds ratios and these were combined by the Mantel-Haenszel method. Main outcome measures: Rates of deep vein thrombosis, pulmonary embolism and wound haematoma.Results: Twenty-one studies involving 4605 patients were included in the meta-analysis. Bemiparin significantly reduces the rates of deep vein thrombosis (OR; 95% CI = 0.38, 0.15-0.90). No significant differences were found in pulmonary embolism and wound haematoma. The incidence of deep vein thrombosis is also lower with enoxaparin than with unfractionated heparin. However, only nadroparin reduced the incidence of pulmonary embolism (ORs = 0.24, 95% CI = 0.05-0.94). In any case, the incidence of wound haematoma was not significant.Conclusion: Bemiparin seems to be as effective and safe as the other low-molecular-weight heparins in the prevention of thromboembolic complications in orthopaedic surgery.

Food Bemiparin Efficacy Low-molecular-weight heparin Meta-analysis Prophylaxis Safety 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Palmer AJ, Schramm W, Kirchhof B, Bergeman R. Low-molecular-weight heparin and unfractionated heparin for prevention of thrombo-embolism in general surgery. A meta-analysis of randomised clinical trials. Haemostasis 1997;27:65–74.Google Scholar
  2. 2.
    Haas S. European consensus statement on the prevention of venous thromboembolism. Blood Coagul Fibrinolysis 1993;4(1):S5–S8.Google Scholar
  3. 3.
    Weitz J. Low-molecular-weight heparins. N Engl J Med 1997;337(10):668–98.Google Scholar
  4. 4.
    Paiement G, Wessinger S, Harris W. Survey of prophylaxis against venous thromboembolism in adults undergoing hip surgery. Clin Orthop 1987;232:188–93.Google Scholar
  5. 5.
    Leyvraz P, Richard J, Bachmann F, Van Melle G, Treyvaud J, Livio J et al. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep vein thrombosis after total hip replacement. N Engl J Med 1983;309:954–8.Google Scholar
  6. 6.
    Fareed J, Jeske W, Hoppednsteadt D, Clarizio R, Walenga J. Are the available low-molecular weight heparin preparations the same? Semin Thromb Hemost 1996;22 (suppl.1):77–91.Google Scholar
  7. 7.
    Fareed J, Jeske W, Eschenfelder V, Igbal O, Hoppensteadt D, Ahsan A. Preclinical studies on a low molecular weight heparin. Thromb Res 1996;81(suppl. 2):S1–S27.Google Scholar
  8. 8.
    Green D, Hirsh J, Heit J, Prins M, Davidson B, Lensing A. Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev 1994;46(1):89–109.Google Scholar
  9. 9.
    Weitz J. Low molecular weight heparins. N Engl J Med 1997;337(10):688–98.Google Scholar
  10. 10.
    Falkon L, Sáenz-Campos D, Antonijoan R, Martin S, Barbanoj MJ, Fontcuberta J. Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11). A three way cross-over study in healthy volunteers. Thromb Res 1995;78(1):77–86.Google Scholar
  11. 11.
    Falkon L, Bayés M, Frontera G, Garj M, Barbanoj M, Fontcuberta J. Pharmacokinetics and tolerability of a new molecular mass heparin (RO-11) in healthy volunteers-A dose-finding study within the therapeutical range. Thromb Haemost 1997;71(1):133–6.Google Scholar
  12. 12.
    Fareed J, Hoppensteadt D, Jeske W, et al. Pharmacology of the low-molecular weight heparins. Semin Thromb Hemost 1996;22(suppl.2):13–8.Google Scholar
  13. 13.
    Kakkar VV, Howes J, Sharma V, Kadziola Z. A comparative, double-blind, randomised trial of a new second generation LMWH (Bemiparin) and UFH in the prevention of post-operative venous thromboembolism. Thromb Haemost 2000;83:523–9Google Scholar
  14. 14.
    Felson DT. Bias in meta-analytic research. J Clin Epidemiol 1992;45:885–92.Google Scholar
  15. 15.
    Nurmohamed M, Rosendaal F, Büller H, Dekker E, Homme D, Van den Broucke J et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340:152–6.Google Scholar
  16. 16.
    Kakkar VV. Efficacy and safety of Clivarin® and others LMWHs in general surgery: a meta-analysis. Blood Coagul Fibrinolysis 1993;4(1):S23–7.Google Scholar
  17. 17.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719–48.Google Scholar
  18. 18.
    Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: Wiley; 1981.Google Scholar
  19. 19.
    Mehta CR, Patel NR, Gray R. Computing an exact confidence interval for common odds ratio in several 2x2 contigency tables. J Am Stat Assoc 1985; 80: 969–73.Google Scholar
  20. 20.
    Einarson TR, Leeder JS, Koren G. A method for meta-analysis of epidemiological studies. Drug Intell Clin Pharm 1988;22:813–24.Google Scholar
  21. 21.
    Koch A, Bouges S, Ziegler S, Dinkel H, Daures J. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical interventions: update of previous meta-analyses. Br J Surg 1997,84:750–9.Google Scholar
  22. 22.
    Colditz G, Burdick E, Mosteller F. Heterogeneity in meta-analysis of data from epidemiological studies. A commentary. Am J Epidemiol 1995;142(4):371–82.Google Scholar
  23. 23.
    Einarson TR, McGhan WF, Bootman JL, Sabers DL. Meta-analysis: quantitative integration of independent research results. Am J Hosp Pharm 1985;42:1957–64.Google Scholar
  24. 24.
    Turpie AGG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ et al. A randomized controlled trial of low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986;315:925–9.Google Scholar
  25. 25.
    Leclerc JR, Geerts WH, Desjardins L, Laroche F, Delorme F, Maviernick S et al. Prevention of deep vein thrombosis after major knee surgery-a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 1992;67:417–23.Google Scholar
  26. 26.
    Jorgensen PS, Knudsen JB, Broeng L, Josephsen L, Bjerregaard P, Hagen K et al. The thromboprophylactic effect of a lowmolecular-weight heparin (Fragmin) in hip fracture surgerya placebo-controlled study. Clin Orthop 1992;278:95–100.Google Scholar
  27. 27.
    Tortholm C, Broeng L, Seest J. Thromboprophylaxis by lowmolecular-weight heparin in elective hip surgery. J Bone Joint Surg Br 1991;73(3):434–8.Google Scholar
  28. 28.
    Lassen MR, Borris LC, Christiansen HM, Boll KL, Eiskjaer SP, Nielsen BW et al. Prevention of thromboembolism in 190 hip arthroplasties. Comparison of LMW heparin and placebo. Acta Orthop Scand 1991;62:33–8.Google Scholar
  29. 29.
    Hoek J, Nurmohamed MT, Hamelynck KJ, Marti RK, Knipscheer HC, ten Cate H, et al. Prevention of deep vein thrombosis (DVT) following total hip replacement by low molecular weight heparinoid (ORG 10172). Throm Haemost 1989;62 (suppl.):520.Google Scholar
  30. 30.
    Leclerc JR, Geerts WH, Desjardins L, L´Esperance B, Demers C, Kassis J et al. Prevention of venous thromboembolism (VTE) after knee arthroplasty-a randomized double-blind trial, comparing enoxaparin to warfarin sodium (abstract). Ann Inter Med 1996;124(7):619–26.Google Scholar
  31. 31.
    Danish Enoxaparin Study Group. Low-molecular-weight heparin (enoxaparin) vs dextran 70. The prevention of postoperative deep vein thrombosis after total hip replacement. Arch Intern Med 1991;151:1621–4.Google Scholar
  32. 32.
    Eriksson BI, Zachrisson BE, Teger-Nilsson AC, Risberg B. Thrombosis prophylaxis with low-molecular weight heparin in total hip replacement. Br J Surg 1988;75:1053–7.Google Scholar
  33. 33.
    Mätzsch T, Bergqvist D, Fredin H, et al. Thromboprophylactic effect of a low molecular weight heparin as compared to dextran in elective hip surgery (abstract). Thromb Haemost 1989;65:520.Google Scholar
  34. 34.
    Mätzsch T, Bergqvist D, Fredin H, Hedner U. Low molecular weight heparin compared with dextran as prophylaxis against thrombosis after total hip replacement. Br J Surg 1988;75:1053–7.Google Scholar
  35. 35.
    Mätzsch T, Bergqvist D, Fredin H, Hedner U. Comparison of the thromboprophylactic effect of a low molecular weight heparin versus dextran in total hip replacement. Thrombotic and Haemorrhagic Disorders 1991;3:25–9.Google Scholar
  36. 36.
    Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallor T et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deepvein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370–6.Google Scholar
  37. 37.
    Planes A, Vochelle N, Fagola M, Bellaud M, Feret J, Salzard C et al. Once-daily dosing of enoxaparin ( a low molecular weight heparin) in prevention of deep vein thrombosis after total hip replacement. Acta Chir Scand 1990; suppl.556:108-15.Google Scholar
  38. 38.
    Planes A. Comparison of antithrombotic efficacy and haemorraghic side-effects of Clivarin® versus enoxaparin in patients undergoing total hip replacement surgery. Blood Coagul Fibrinolysis 1993;4(suppl. 1):S33–5.Google Scholar
  39. 39.
    Roise O, Nurmohamed M, Reijnders P. A multicentre randomised, assesor-blind, pilot study comparing the efficacy in the prophylaxis of DVT and the safety of Orgaran® (Org 10172), Fragmin®, Clexane®/Lovenox® in patients undergoing surgery for a fractured hip (abstract). Thromb Haemost 1993;65(5):620.Google Scholar
  40. 40.
    Reilman H, Bosch U, Creutrig H. Thromboseprophylaxe mit niedermolekularem Heparin plus Dihydroergotamin bei Operationen an den unteren Extremitäten. Perfusion 1989;6:230–4.Google Scholar
  41. 41.
    Levine M, Hirsh J, Gent M, Turpie AG, Leclerc J, Powers PJ et al. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991;114:545–51.Google Scholar
  42. 42.
    Planes A, Vochelle N, Mazas F, Mansat C, Zucman J, Landais A et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemostas 1988;60(3):407–10.Google Scholar
  43. 43.
    Colwell C, Spiro T, Trowbridge A, Morris BA, Kwaan HL, Blaha JD et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. J Bone and Joint Surg Br 1994;76(1):3–14.Google Scholar
  44. 44.
    Avikainen V, von Bonsdorff H, Partio E, Kaira P, Hakkinen S, Usenius JP et al. Low molecular weight heparin (enoxaparin) compared with unfractionated heparin in prophylaxis of deep venous thrombosis and pulmonary embolism in patients undergoing hip replacement. Ann Chir Gynaecol 1995;84:85–90.Google Scholar
  45. 45.
    Spiro T, Colwell, Bona A. Enoxaparin versus unfractionated heparin for prevention of venous thromboembolic disease after elective knee replacement surgery (abstract). Chest 1994;106(suppl.2):485.Google Scholar
  46. 46.
    Fauno P, Suomalainen O, Rehnberg V, Hansen TB, Kroner K, Sormakellios S et al. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. J Bone and Joint Surg 1994;76(12):1814–8.Google Scholar
  47. 47.
    Eriksson B, Kälebo P, Anthmyr B, Wadenvik H, Tengborn L, Risberg B et al. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular weight heparin and unfractionated heparin. J Bone and Joint Surg 1991;73(4):484–93.Google Scholar
  48. 48.
    Monreal M, Lafoz E, Navarro A, Granero X, Caja V, Caceres E et al. A prospective double-blind trial of low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fracture. J Trauma 1989;29(6):873–5.Google Scholar
  49. 49.
    Dechavanne M, Ville D, Berruyer M, Trepo F, Dalery F, Clermont N et al. Randomized trial of a low-molecular weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective surgery. Haemostasis 1989;1:5–12.Google Scholar
  50. 50.
    Breyer G, Rahmanzadeh R, Bacher P. LMW-heparin versus heparin-DHE in orthopaedic surgery (abstract). Thromb Haemost 1987;58:241.Google Scholar
  51. 51.
    Binsack T, Zellner M, Schimming I, et al. Thrombosis prophylaxis with LMW heparin and sodium heparin in patients with total hip replacement (abstract). Thromb Res 1986;(suppl. 6):83.Google Scholar
  52. 52.
    Barre J, Pfister G, Potron G, Droulle C, Baudullard JL, Barbier P et al. efficacité et tolérance comparée du Kabi 2165 et de l`héparine standard dans la prévention des thromboses veineuses profondes au cours des prothèses totales de hanche. J Mal Vasc 1987;12:90–5.Google Scholar
  53. 53.
    The German Hip Arthroplasty Trial (GHAT) group. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement. A randomized trial. Arch Orthop Trauma Surg 1992;111:110–20.Google Scholar
  54. 54.
    Leyvraz P, Bachmann F, Hoek J, Buller HR, Postel M, Samama M et al. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ 1991;303:543–8.Google Scholar
  55. 55.
    Haas S, Stemberger A, Fritsche H, Welzel D, Wolf H, Lechnert F et al. Prophylaxis of deep vein thrombosis in high risk patients undergoing total hip replacement with low molecular weight heparin plus dihydroergotamine. Drug Res 1987;37:839–43.Google Scholar
  56. 56.
    Korninger C, Schlag G, Poigenfürst J. Randomized trial of low molecular weight heparin (LMWH) versus low dose heparin/acenocoumarin (H/AC) in patients with hip fracture-Thromboprophylactic effect and bleeding complications. Thromb Haemost 1989;62:187.Google Scholar
  57. 57.
    Lassen M, Borris L, Christiansen H, Moller-Larsen F, Knudsen VE, Boris P et al. Heparin/dihydroergotamine for venous thrombosis prophylaxis: comparison of low-dose heparin and low molecular weight heparin in hip surgery. Br J Surg 1988;75:686–9.Google Scholar
  58. 58.
    Lassen M, Borris L, Christiansen H, Moller-Larsen F, Boris P, Knudsen VE et al. Prevention of thromboembolism in hipfracture patients. Comparison of low-dose heparin and low molecular-weight heparin combined with dihydroergotamine. Arch Orthop Trauma Surg 1989;108:10–3.Google Scholar
  59. 59.
    Freick H, Haas S. Prevention of deep vein thrombosis by lowmolecular-weight heparin and dihydroergotamine in patients undergoing total hip replacement. Thromb Res 1991;63:133–43.Google Scholar
  60. 60.
    Pini M, Tagliaferri A, Manotti C, Lasagni F, Rinaldi E, Deltori AG. Low molecular weight heparin (alfa LMWH) compared with unfractionated heparin in prevention of deep-vein thrombosis after hip fractures. Inter Angio 1989;8:134–9.Google Scholar
  61. 61.
    Chiapuzzo E, Orengo G, Ottria G, Chiapuzzo A, Palazzini E, Fusillo M. The use of low molecular weight heparins for postsurgical deep vein thrombosis prevention in orthopaedic patients. J Inter Med Res 1988;16:359–66.Google Scholar
  62. 62.
    Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparison in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50(6):683–91.Google Scholar
  63. 63.
    Jorgenesen LN, Wille-Jorgensen P, Hauch O. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. Br J Surg 1993;80:689–704.Google Scholar
  64. 64.
    Lassen MR, Borris LC, Christiansen HM, Schott P, Olsen AD, Sorensen JV et al. Clinical trials with low molecular weight heparins in the prevention of postoperative thromboembolic complications: a meta-analysis. Semin Thromb Hemost 1991;17(suppl.3):284–90.Google Scholar
  65. 65.
    Hull RD, Brant TF, Pineo GE. Pre-operative versus postoperative initiation of low molecular weight heparin prophylaxis against thromboembolism in patients undergoing elective hip replacement. Arch Intern Med 1999;159(2):137–41.Google Scholar
  66. 66.
    Fontcuberta J. Kinetic behaviour of the TFPI and anti-FXa effects, after the injection of a LMWH (RO-11) in healthy subjects. Thromb Haemostas 1995;73(4):727–38.Google Scholar
  67. 67.
    Abildgaard U. Heparin/low molecular weight heparin and tissue factor pathway inhibitor. Haemostasis 1993; 23(suppl.1):103–6.Google Scholar
  68. 68.
    Kakkar VV. Cost-effectiveness of the low molecular weight heparin reviparin sodium in thromboprophylaxis. Thromb Res 1996;81(2):S75–7.Google Scholar
  69. 69.
    Heaton D, Pearce M. Low molecular weight versus unfractionated heparin. A Clinical and Economic appraisal. PharmacoEconomics 1995,8(2):91–9.Google Scholar
  70. 70.
    Andersson DR, O´Brien BJ, Levine MN. Efficacy and cost of low-molecular weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 1993;119:1105–12.Google Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • R. Ferriols-Lisart
    • 1
  • F. Ferriols-Lisart
    • 2
  • V. Jimnez-Torres
    • 3
    • 4
  1. 1.Pharmacy ServiceGeneral HospitalCastellönSpain
  2. 2.Pharmacy ServiceClinic University HospitalValenciaSpain
  3. 3.Pharmacy ServiceUniversity Hospital Dr.PesetValenciaSpain
  4. 4.Pharmacy and Pharmaceutical Technology DepartmentUniversity of ValenciaSpain

Personalised recommendations